XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
  AIDS
  Influenza
  MRSA
  Tuberculosis
  Shigella
  HCV
  SARS
  Ebola
  Dengue
  Malaria
  Pertussis
  Mumps
  Prion Diseases
  Small Pox
  Anthrax
  Leishmaniasis
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Liver Transplantation; February 2006

HCV Channel
subscribe to HCV newsletter

Latest Research : Infectious Diseases : HCV

   DISCUSS   |   EMAIL   |   PRINT
Extrahepatic sites may cause rapid recurrence of Hepatitis C after liver transplantation
Feb 3, 2006, 16:03, Reviewed by: Dr. Rashmi Yadav

"In most patients HCV RNA levels decreased rapidly during and after transplantation and subsequently began to increase � reaching above pre-transplant levels in all but one patient � within a few days of the procedure."

 
When a diseased liver is removed from a patient with Hepatitis C (HCV), serum viral levels plummet. However, after receiving a healthy liver transplant, virus levels rebound and can surpass pre-transplant levels within a few days, according to a new study published in the February 2006 issue of Liver Transplantation, the official journal of the American Association for the Study of Liver Diseases (AASLD) and the International Liver Transplantation Society (ILTS).

Hepatitis C is the number one reason for liver transplantation, however, the virus always recurs in the new liver. Since mathematical models have been useful in the study of the viral dynamics of HIV and hepatitis B, researchers, led by Kimberly A. Powers and Ruy M. Ribeiro of the Los Alamos National Laboratory in New Mexico, sought to use a mathematical model to quantify the liver reinfection dynamics of HCV.

The researchers, in collaboration with a surgical team lead by John McHutchison now at Duke University Medical Center, followed six HCV-infected patients who received cadaveric liver transplants. They collected blood samples before, during and after transplantation to assess changing levels of HCV RNA which was measured using reverse transcription polymerase chain reaction assay. They then plugged the data into a mathematical model, correcting for fluid balance, and analyzed the results using linear regression.

"In most patients," the authors report, "HCV RNA levels decreased rapidly during and after transplantation and subsequently began to increase � reaching above pre-transplant levels in all but one patient � within a few days of the procedure." They found that when the diseased liver was removed, virus levels dropped with an average half-life of 48 minutes. After the new liver was implanted, they found that virus levels continued to drop for up to 23 hours, then began to rise, doubling every 2 days.

Notably, in three patients, the virus levels plateaued before rising, suggesting, say the authors "that a non-hepatic source supplied virions and balanced their intrinsic clearance." The authors estimate, however, that non-hepatic sources can only account for 4 percent of total viral production. Ninety-six percent of it occurs in the liver.

The patterns of viremia decline and increase seen in this study are consistent with previous studies, although this study indicates a much faster virion half-life than previously suggested. The findings also support the notion that HCV can replicate rapidly in the post-transplant immunosuppressed patient, leading the authors to suggest that early antiviral therapy may delay or prevent reinfection.

The study was limited by the small number of patients and the single compartment model, which did not separately account for liver and extrahepatic sites of viral replication. "Nevertheless," report the authors, "the rapid HCV RNA decline in the anhepatic phase, followed by the postoperative increase observed in several patients�suggest that the liver is the primary site of viral replication, with at most small contributions from extrahepatic sites."

In conclusion, the authors write, "Continued work towards elucidating extrahepatic replication, the time-course of reinfection, the effects of immunosuppressive therapy, and the relationships among viremia, infection and liver damage will be beneficial in optimizing treatment for HCV patients undergoing liver transplantation."
 

- "Kinetics of Hepatitis C Virus Reinfection After Liver Transplantation," Kimberly A. Powers, Ruy M. Ribeiro, Keyur Patel, Stephen Pianko, Lisa Nyberg, Paul Pockros, Andrew Conrad, John McHutchison, and Alan S. Perelson, Liver Transplantation; February 2006; (DOI: 10.1002/lt.20572).
 

www.interscience.wiley.com/journal/livertransplantation

 
Subscribe to HCV Newsletter
E-mail Address:

 

February 2006 issue of Liver Transplantation, the official journal of the American Association for the Study of Liver Diseases (AASLD) and the International Liver Transplantation Society (ILTS). The journal is published on behalf of the societies by John Wiley & Sons, Inc. and is available online via Wiley InterScience

Related HCV News

Bavituximab Shows Promising Anti-Viral Activity in Monotherapy HCV Trial
Treating obesity improves efficacy of hepatitis C therapy
Molecular mechanism that inhibits HCV replication discovered - Tang-Nelson study
Extrahepatic sites may cause rapid recurrence of Hepatitis C after liver transplantation
How Hepatitis C virus highjack protein synthesis machinery in humans
Breastfeeding does not raise risk of HCV transmission
Celgosivir Cleared for Phase IIb Combination Study in HCV Non-responders
Albuferon in Phase 2b Trial for the Treatment of Chronic Hepatitis C
Valopicitabine Shows Potential Therapeutic Response in the Treatment of Genotype 1 Hepatitis C Patients


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us